Atorvastatin/fenofibrate - Chong Kun Dang

Drug Profile

Atorvastatin/fenofibrate - Chong Kun Dang

Alternative Names: Atorvastatin calcium trihydrate/choline fenofibrate; CKD-337; Fenofibrate/atorvastatin - Chong Kun Dang

Latest Information Update: 18 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chong Kun Dang
  • Class Antihyperlipidaemics; Butyric acids; Fatty acids; Fluorobenzenes; Heptanoic acids; Propionates; Pyrroles; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dyslipidaemias

Most Recent Events

  • 01 May 2016 Chong Kun Dang Pharmaceutical completes a phase I trial in Dyslipidaemias (In volunteers) in South Korea (NCT02651753)
  • 01 Feb 2016 Preclinical trials in Dyslipidaemias (In volunteers) in South Korea (PO) before February 2016
  • 01 Feb 2016 Chong Kun Dang Pharmaceutical plans a pharmacokinetics phase I trial in Healthy male volunteers in South Korea (PO) (NCT02651753)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top